ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
Company continues to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ('ESSA,' or the 'Company') (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025.
'We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value,' said David Parkinson, MD, President and CEO of ESSA. 'We have taken productive steps towards a decision and hope to share an update in the near future.'
Second Quarter 2025 and Recent Updates
Summary of Financial Results
(Amounts expressed in U.S. dollars)
Liquidity and Outstanding Share Capital
About ESSA Pharma Inc.
ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.
Forward-Looking Statement Disclaimer
This release contains certain information which, as presented, constitutes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and 'forward-looking information' within the meaning of applicable Canadian securities laws (collectively, 'forward-looking statements'). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as 'anticipate', 'believe', 'plan', 'estimate', 'expect', and 'intend', statements that an action or event 'may', 'might', 'could', 'should', or 'will' be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the termination of the Company's clinical studies of masofaniten, the Company's evaluation of its strategic alternatives and future announcements in connection therewith and the Company's expected headcount and cost reductions.
Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections; (ii) obtaining necessary regulatory approvals; (iii) ESSA's ability to efficiently wind down its clinical trial activities (iv) that one or more strategic options may be available to ESSA at reasonably acceptable terms; and (v) general business, market and economic conditions.
Forward-looking statements are developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 10-K dated December 17, 2024, under the heading 'Risk Factors', a copy of which is available on ESSA's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca, and as otherwise disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable United States and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.
Contacts
ESSA Pharma Inc.
David Wood, Chief Financial Officer
778.331.0962
[email protected]
Investors and Media
Argot Partners
212.600.1902
[email protected]
ESSA PHARMA INC.
CONSOLIDATED BALANCE SHEETS
Unaudited
Amounts in thousands of United States dollars
ESSA PHARMA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Unaudited
Amounts in thousands of United States dollars, except share and per share data
View original content: https://www.prnewswire.com/news-releases/essa-pharma-reports-financial-results-for-fiscal-second-quarter-ended-march-31-2025-302449410.html
SOURCE ESSA Pharma Inc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025
NEW YORK, June 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of May 31, 2025, an increase of $1.1 billion from assets under management of $87.5 billion at April 30, 2025. The increase was due to market appreciation of $1.3 billion, partially offset by distributions of $150 million and net outflows of $88 million. Assets Under Management (unaudited) ($ in millions) AUM Net MarketAUM By investment vehicle: 4/30/2025 Flows App/(Dep) Distributions 5/31/2025 Institutional Accounts: Advisory $19,937 $10 $352 - $20,299 Subadvisory 14,091 (19) 306 (57) 14,321 Total Institutional Accounts 34,028 (9) 658 (57) 34,620 Open-end Funds 42,210 (80) 510 (42) 42,598 Closed-end Funds 11,271 1 176 (51) 11,397 Total AUM $87,509 ($88) $1,344 ($150) $88,615 About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore. View original content: SOURCE Cohen & Steers, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Ondas Holdings Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, MA / / June 9, 2025 / Ondas Holdings Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of private industrial wireless networks and commercial drone and automated data solutions through its Ondas Networks and Ondas Autonomous Systems business units, today announced that it intends to offer and sell shares of its common stock and in lieu of common stock, pre-funded warrants to purchase shares of its common stock. Ondas also expects to grant the underwriter a 30-day option to purchase additional shares of common stock offered in the public offering. All of the securities in the proposed offering are to be sold by Ondas. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Ondas intends to use the net proceeds from the proposed offering for general corporate purposes, including funding capital expenditures and providing working capital. Oppenheimer & Co. Inc. is acting as the sole underwriter for the offering. A shelf registration statement on Form S-3 (File No. 333-286642) relating to the securities to be issued in the proposed offering was filed with the Securities and Exchange Commission ("SEC") on April 18, 2025 and was declared effective on April 25, 2025. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@ Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC's website at The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Forward-Looking Statements Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion and anticipated use of proceeds of the proposed offering. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties relate, among other things, to fluctuations in our stock price, changes in market conditions and satisfaction of customary closing conditions related to the proposed public offering. Our actual results, performance, or achievements, including our ability to conduct and complete a public offering of our common stock on terms acceptable to us or at all, could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law. ContactsIR Contact for Ondas Holdings Inc.888.350.9994ir@ Media Contact for OndasEscalate PRondas@ Preston GrimesMarketing Manager, Ondas Holdings SOURCE: Ondas Holdings Inc. View the original press release on ACCESS Newswire
Yahoo
15 minutes ago
- Yahoo
Warner Bros. Discovery Stock Enjoys Big Jump, Then Promptly Fades After Split Announcement
Warner Bros. Discovery's plan to split into two publicly traded companies sent its stock price surging higher on Monday morning, with shares of WBD jumping 13% to $11.10 on the Nasdaq exchange only minutes after the opening bell. Those early gains started to fade by midday, though, with Warner Bros. Discovery's stock trading for $9.94 per share at 1 p.m. ET — up 1.30% from where it closed last week. Here is an up-to-the-minute look at WBD: On the year, WBD is down 6%, and the company's stock price has been more than sliced in half since it debuted on the Nasdaq in 2022 for $24.08 per share. That came after WarnerMedia and Discovery merged — a move that was met with a collective shrug from Wall Street analysts and investors from the start, with its stock price increasing 0.8% on April 11, 2022, its first day of trading. Now, three years later, WBD announced on Monday it will split into two companies, with one company focused on its global cable channels and another dedicated to its movie and streaming businesses. David Zaslav, president and CEO of WBD, will become president and CEO of Streaming & Studios, while Gunnar Wiedenfels, WBD's CFO, will serve as president and CEO of Global Networks. The separation is expected to be completed by mid-2026. 'By operating as two distinct and optimized companies in the future, we are empowering these iconic brands with the sharper focus and strategic flexibility they need to compete most effectively in today's evolving media landscape,' Zaslav said in a statement. The new Streaming & Studios operation will consist of Warner Bros. Television, Warner Bros. Motion Picture Group, DC Studios, HBO and HBO Max, in addition to their corresponding film and television libraries. Global Networks, meanwhile, will include international entertainment, sports and TV news brands such as CNN, TNT Sports, Discovery, Discovery+, Bleacher Report and European free-to-air channels. In related news, WBD investors last week voted to reject a $51.9 million compensation package for Zaslav. The post Warner Bros. Discovery Stock Enjoys Big Jump, Then Promptly Fades After Split Announcement appeared first on TheWrap. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
